




## **Analysis Report**


























## Chemotherapy Multiplots







		Missing	Overall
n			2552
age at dx, mean (SD)		0	62.0 (11.7)
time, mean (SD)		0	4.8 (2.8)
Dose, mean (SD)		0	66.9 (5.6)
T Stage, n (%)	Other		3 (0.1)
T Stage, n (%)	T1		361 (14.1)
T Stage, n (%)	T1a		147 (5.8)
T Stage, n (%)	T1b		68 (2.7)
T Stage, n (%)	T2		747 (29.3)
T Stage, n (%)	Т3		704 (27.6)
T Stage, n (%)	T4		96 (3.8)
T Stage, n (%)	T4a		295 (11.6)
T Stage, n (%)	T4b		95 (3.7)
T Stage, n (%)	Tis		36 (1.4)
Disease Site, n (%)	Other		26 (1.0)
Disease Site, n (%)	hypopharynx		143 (5.6)
Disease Site, n (%)	larynx		727 (28.5)
Disease Site, n (%)	lip & oral cavity		82 (3.2)
Disease Site, n (%)	nasal cavity		51 (2.0)
Disease Site, n (%)	nasopharynx		321 (12.6)
Disease Site, n (%)	oropharynx		1176 (46.1)
Disease Site, n (%)	paranasal sinus		26 (1.0)
N Stage, n (%)	NO		914 (35.8)
N Stage, n (%)	N1		260 (10.2)
N Stage, n (%)	N2		161 (6.3)
N Stage, n (%)	N2a		75 (2.9)
N Stage, n (%)	N2b		585 (22.9)
N Stage, n (%)	N2c		409 (16.0)
N Stage, n (%)	N3		106 (4.2)
N Stage, n (%)	N3b		27 (1.1)
N Stage, n (%)	Other		15 (0.6)
Sex, n (%)	Female		513 (20.1)
Sex, n (%)	Male		2039 (79.9)
Stage, n (%)	0		37 (1.4)
Stage, n (%)	l _		289 (11.3)
Stage, n (%)	II		323 (12.7)

		Missing	Overall
Stage, n (%)	III		474 (18.6)
Stage, n (%)	IVA		1187 (46.5)
Stage, n (%)	IVB		228 (8.9)
Stage, n (%)	Other		11 (0.4)
Stage, n (%)	Unknown		3 (0.1)
event, n (%)	0		1674 (65.6)
event, n (%)	1		878 (34.4)
Chemotherapy, n (%)	0		1466 (57.4)
Chemotherapy, n (%)	1		1086 (42.6)
EGFRI, n (%)	0		2452 (96.1)
EGFRI, n (%)	1		100 (3.9)
HPV Combined, n (%)	0.0		437 (17.1)
HPV Combined, n (%)	1.0		840 (32.9)
HPV Combined, n (%)	Unknown		1275 (50.0)